Newsletter | August 14, 2025

08.14.25 -- Advanced Manufacturing And CDMOs Are Rewriting The CGT Cost Equation

SPONSOR

Join Bioprocess Online Live on September 9 at 11am ET for a Q&A with CMC and MSAT experts about how companies can align their teams to overcome internal barriers and unlock the promise of PATs. Registration is free for this digital event.

FOCUS ON OUTSOURCING

Advanced Manufacturing And CDMOs Are Rewriting The CGT Cost Equation

Without contract manufacturers, small biotechs often don't stand a chance of reaching commercial production scales, let alone global access for their drugs.

How-To Master Tech Transfer: Strategies To Sidestep Common Pitfalls

Ensure a smooth and efficient technology transfer by following key strategies and avoiding common pitfalls to streamline your process and achieve consistent, error-free results.

5 Ways Pre-Filled Syringes Contribute To Better Patient Outcomes

In our series on pre-filled syringes, we explore five key ways this delivery format is enhancing patient outcomes, not just through the medicine it contains, but through the device design itself.

De-Risking A Bioconjugate's Development Path From Discovery To Clinic

Understanding the obstacles you may face during bioconjugate development, as well as the tools available to help overcome them, can help streamline your product’s path to market.

Collaborate With A Partner To Bring Your Rare Disease Therapy To Clinic

Choosing the CDMO best suited to manufacture your rare disease therapy can be challenging. Ideally, a CDMO will prioritize your goals while working to ensure quality and regulatory success.

OUTSOURCING SOLUTIONS

Capacity Update January 2025: Large Molecule Development - Catalent

End-To-End Clinical And Commercial Manufacturing Support - Abzena

Drug Characterization And Release Testing Services - Mabion

Connect With Bioprocess Online: